France to Ban HHC Synthetic Cannabis in Weeks

May.16.2023

France's Health Minister plans to ban HHC products, created from synthetic cannabis extract, within weeks due to regulatory loopholes.

Statement:

This article is solely focused on conducting research on related industries and foreign markets. It does not make recommendations on any products, nor does it provide commentary on any domestic policies pertaining to the industry.

The legality of the product mentioned in the article is limited to overseas only. Domestic readers are reminded to strictly abide by relevant laws and regulations in China.

This article does not provide any investment or consumption advice.

This article is not suitable for minors.

On May 15th, François Braun, the French Minister of Health, announced that products containing HHC (hexahydrocannabinol) may be banned in a few weeks.

When asked about issues related to hexahydrocannabinol (HHC) by the media, Braun told French radio station, "...

I believe that this (ban) will only be in effect for a few weeks.

According to reports, HHC is a molecule artificially synthesized from natural cannabis extract, and products based on HHC are currently not subject to sales or consumption restrictions in France.

In the past few months, health authorities in various countries, both in Europe and the United States, have noticed an increase in the sale of a certain substance through online or physical stores. Currently, not much is known about its effects, but addiction experts believe it has similar effects to tetrahydrocannabinol (THC), which is the primary psychoactive ingredient in cannabis.

Braun explained, "Currently, they are not classified as drugs. But I believe they will soon be.

Braun likened HHC to a regulatory loophole.

There is a loophole that needs to be quickly filled so that we no longer have such completely abnormal sales.

Reference:

The Health Minister announces that synthetic cannabis, HHC, will be banned within a few weeks.

#North America #United States #Market #Disposable e-cigarettes #France #Legislation France #Synthetic marijuana #Cannabis vaporization #Synthetic nicotine e-cigarettes

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

BAT accused of “utter hypocrisy” over efforts to dilute Zambia’s tobacco bill

The Guardian reports that British American Tobacco urged Zambian ministers to drop or delay ad and sponsorship bans and to soften a draft tobacco bill by shrinking health warnings, easing flavour restrictions and lowering penalties. Critics said the stance is hypocritical given similar rules apply in the UK.

Nov.13

CNIPA Targets E-Cigarettes as Key Focus in Crackdown on Trademark Violations

National Intellectual Property Office issued a notice to strengthen management of illegal use of trademarks, promoting fair competition.

Nov.25 by 2FIRSTS.ai

Imperial Brands launches ZONE nicotine pouches in the UK, covering the core 9–12 mg strength segment

Imperial Brands has launched its ZONE nicotine pouches in the UK, targeting the mainstream 9–12 mg nicotine strength segment. The brand debuts with five flavours at a recommended retail price of £6.50 per can. Mint variants currently account for around 70% of UK nicotine pouch sales, while fruit flavours are growing rapidly. ZONE will be distributed primarily through independent retail channels.

Nov.18 by 2FIRSTS.ai

5th Circuit Reviews FDA’s Compliance on Small-Business Impact of Vape Rule

A Fifth Circuit panel expressed doubts about whether the U.S. Food and Drug Administration complied with the Regulatory Flexibility Act when issuing its 2021 final rule on premarket tobacco product applications. Vape companies argued the FDA relied on outdated and inaccurate economic data, while the government said the challenged requirements stem from the Tobacco Control Act.

Dec.03 by 2FIRSTS.ai